A Phase 1A Single Ascending Dose and Multiple Ascending Dose Double-Blind, Placebo-Controlled, Randomized Trial of Oral Inhalation PK10571 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2018
At a glance
- Drugs PK 10571 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Pulmokine
- 20 Mar 2018 Status changed from planning to recruiting.
- 05 Mar 2015 New trial record
- 03 Mar 2015 Pulmokine expects to submit an IND application to the US FDA in the fourth quarter of 2015, and commence this phase 1 trial following the clearance of that application, according to a media release.